Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Belani

Showing results (81-90 of 298) with videos related to

Pageof 30
Sort By:
Cancer Treatment and Research|February 28, 2001
Lung cancer: therapeutic options for stage IV and recurrent NSCLCA R Calvo, C P Belani
Current Opinion in Oncology|December 17, 2009
Antiangiogenic agents in the treatment of nonsmall cell lung cancer: reality and hopeSuresh S Ramalingam, Chandra P Belani
Seminars in Oncology|August 1, 1997
Chemotherapy for advanced non-small cell lung cancer: past, present, and futureR K Ramanathan, C P Belani
Chest|January 23, 1998
Combined-modality treatment of locally advanced non-small cell lung cancer: incorporation of novel chemotherapeutic agentsC P Belani, R K Ramanathan
Plos One|December 2, 2021
Diversity and heterogeneity of immune states in non-small cell lung cancer and small cell lung cancerShawn J Rice, Chandra P Belani
Expert Opinion on Pharmacotherapy|March 13, 2012
Maintenance therapy for advanced non-small-cell lung cancer: switch versus continuationMonika Joshi, Yixing Jiang, Chandra P Belani
Expert Review of Anticancer Therapy|March 11, 2005
Docetaxel in advanced non-small cell lung cancerHeather Wakelee, Sakkaraiappan Ramalingam, Chandra P Belani
Cancer Treatment Reviews|July 1, 2011
Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC)C P Belani, G Goss, G Blumenschein
Advances in Experimental Medicine and Biology|January 5, 2013
Small-cell lung cancer: an update on targeted therapiesMonika Joshi, Ayodele Ayoola, Chandra P Belani
Anti-Cancer Drugs|January 28, 2014
Taxanes, past, present, and future impact on non-small cell lung cancerMonika Joshi, Xin Liu, Chandra P Belani
Pageof 30

Showing results (81-90 of 298) with videos related to

Sort By:
Pageof 30
Cancer Treatment and Research|February 28, 2001
Lung cancer: therapeutic options for stage IV and recurrent NSCLCA R Calvo, C P Belani
Current Opinion in Oncology|December 17, 2009
Antiangiogenic agents in the treatment of nonsmall cell lung cancer: reality and hopeSuresh S Ramalingam, Chandra P Belani
Seminars in Oncology|August 1, 1997
Chemotherapy for advanced non-small cell lung cancer: past, present, and futureR K Ramanathan, C P Belani
Chest|January 23, 1998
Combined-modality treatment of locally advanced non-small cell lung cancer: incorporation of novel chemotherapeutic agentsC P Belani, R K Ramanathan
Plos One|December 2, 2021
Diversity and heterogeneity of immune states in non-small cell lung cancer and small cell lung cancerShawn J Rice, Chandra P Belani
Expert Opinion on Pharmacotherapy|March 13, 2012
Maintenance therapy for advanced non-small-cell lung cancer: switch versus continuationMonika Joshi, Yixing Jiang, Chandra P Belani
Expert Review of Anticancer Therapy|March 11, 2005
Docetaxel in advanced non-small cell lung cancerHeather Wakelee, Sakkaraiappan Ramalingam, Chandra P Belani
Cancer Treatment Reviews|July 1, 2011
Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC)C P Belani, G Goss, G Blumenschein
Advances in Experimental Medicine and Biology|January 5, 2013
Small-cell lung cancer: an update on targeted therapiesMonika Joshi, Ayodele Ayoola, Chandra P Belani
Anti-Cancer Drugs|January 28, 2014
Taxanes, past, present, and future impact on non-small cell lung cancerMonika Joshi, Xin Liu, Chandra P Belani
Pageof 30